892-49-9

Basic information

• Product Name: 6-MERCAPTOPURINE ARABINOSIDE
• Synonyms: arabinofuranosyl-6-mercaptopurine;arabinosyl-6-mercaptopurine;beta-ara-6-mp;9-beta-D-arabinofuranosyl-1,9-dihydro-6H-purine-6-thione;9-β-D-Arabinofuranosyl-9H-purine-6-thiol;Ara-mp;NSC-406021;.beta.-D-Arabinofuranosyl-6-mercaptopurine
• CAS NO: 892-49-9
• Molecular Formula: C₁₀H₁₂N₄O₄S
• Molecular Weight: 284.29168
• EINECS: 212-968-3
• Mol File: 892-49-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 714.7°C at 760 mmHg
• Flash Point: 386°C
• Appearance: /
• Density: 2.02g/cm³
• Vapor Pressure: 1.95E-21mmHg at 25°C
• Refractive Index: 1.904
• Storage Temp.: -20°C
• PKA: 8.40±0.20(Predicted)
• CAS DataBase Reference: 6-MERCAPTOPURINE ARABINOSIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-MERCAPTOPURINE ARABINOSIDE(892-49-9)
• EPA Substance Registry System: 6-MERCAPTOPURINE ARABINOSIDE(892-49-9)

Safety Data

• Hazardous Substances Data: 892-49-9(Hazardous Substances Data)

Usage

General Description

6-Mercaptopurine arabinoside is a chemical compound used in cancer treatment as an antimetabolite. It belongs to the class of purine analogues and has the potential to disrupt the growth of cancer cells by interfering with their DNA and RNA synthesis. 6-MERCAPTOPURINE ARABINOSIDE has been particularly effective in the treatment of acute leukemias and various other types of cancer. 6-Mercaptopurine arabinoside is typically administered in combination with other chemotherapy drugs to achieve a more comprehensive and effective treatment. It is important to note that the use of this compound should be closely monitored by a healthcare professional due to its potential for adverse effects and interactions with other medications.

InChI:InChI=1/C10H12N4O4S/c15-1-4-6(16)7(17)10(18-4)14-3-13-5-8(14)11-2-12-9(5)19/h2-4,6-7,10,15-17H,1H2,(H,11,12,19)/t4-,6-,7+,10-/m1/s1

Upstream product

• 108321-99-9 α,β-D-arabinofuranose-5-phosphate disodium salt 
• 157930-09-1 6-Mercaptopurine 
• 2004-06-0 2-(6-chloropurin-9-yl)-5-hydroxymethyltetrahydrofuran-3,4-diol 
• 38819-10-2 9-β-D-arabinofuranosylguanine 
• 50-44-2 6-mercaptopurine 
• 5536-17-4 arabinosyl adenine 

Downstream Products

• 76265-59-3 9-β-D-arabinofuranosylpurine-6-carboxamide 

Relevant articles and documents

Heterocyclic compound containing SCF3 or SeCF3, and preparation method thereof

The invention discloses a heterocyclic compound containing SCF3 or SeCF3, and a preparation method thereof. The preparation method comprises: dissolving a chlorinated heterocyclic compound 1 in an EtOH solution, adding 1.0-2.0 equivalent weight of thiourea or selenourea, then stirring for 1-8 hours at 50-120 DEG C, and reacting to obtain a compound 2; and dissolving the compound 2 in an Acetone orEA solution, adding 2.0-4.0 equivalent weight of CF3SO2Na and 0.2-0.4 equivalent weight of a Cu salt, adding 2.0-4.0 equivalent weight of a tBuOOH solution in a dropwise manner, and reacting at 25-40DEG C for 1.0-2.0 hours to obtain a compound 3, namely the required SCF3 or SeCF3-containing heterocyclic compound. According to the invention, the synthesized compound has huge potential in the aspect of treating diseases; and according to the synthetic route provided by the invention, amplification can be realized in each step, the yield can reach 85%, the synthetic route provided by the invention brings a simpler and more effective way for synthesis of compounds with biological activity, the yield is high, large-scale preparation can be realized, and the synthetic route has a very wide application prospect.

Enzymatic Synthesis of Therapeutic Nucleosides using a Highly Versatile Purine Nucleoside 2’-DeoxyribosylTransferase from Trypanosoma brucei

The use of enzymes for the synthesis of nucleoside analogues offers several advantages over multistep chemical methods, including chemo-, regio- and stereoselectivity as well as milder reaction conditions. Herein, the production, characterization and utilization of a purine nucleoside 2’-deoxyribosyltransferase (PDT) from Trypanosoma brucei are reported. TbPDT is a dimer which displays not only excellent activity and stability over a broad range of temperatures (50–70 °C), pH (4–7) and ionic strength (0–500 mM NaCl) but also an unusual high stability under alkaline conditions (pH 8–10). TbPDT is shown to be proficient in the biosynthesis of numerous therapeutic nucleosides, including didanosine, vidarabine, cladribine, fludarabine and nelarabine. The structure-guided replacement of Val11 with either Ala or Ser resulted in variants with 2.8-fold greater activity. TbPDT was also covalently immobilized on glutaraldehyde-activated magnetic microspheres. MTbPDT3 was selected as the best derivative (4200 IU/g, activity recovery of 22 %), and could be easily recaptured and recycled for >25 reactions with negligible loss of activity. Finally, MTbPDT3 was successfully employed in the expedient synthesis of several nucleoside analogues. Taken together, our results support the notion that TbPDT has good potential as an industrial biocatalyst for the synthesis of a wide range of therapeutic nucleosides through an efficient and environmentally friendly methodology.

Purine sugar derivatives

This invention relates to purine sugar derivatives which are useful as suppressors of the immune response and as antiviral agents, and to methods of preparation thereof.